The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.

In 2025, eligible pregnant women will be able to receive the respiratory syncytial virus (RSV) vaccine for free under the ...

Last year, a prenatal maternal vaccine (Avrexy) and a long-lasting monoclonal antibody called nirsevimab were approved for ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance for seniors. Carina Marquez, MD, associate professor of Medicine in ...

Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older – ...